Skip to search formSkip to main contentSkip to account menu

pembrolizumab

Known as: Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide, Lambrolizumab 
A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death… 
National Institutes of Health

Related topics

Related topics

10 relations
4 ML pembrolizumab 25 MG/ML Injection4 ML pembrolizumab 25 MG/ML Injection [Keytruda]Monoclonal AntibodiesNCIt Antineoplastic Agent Terminology

Broader (2)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents

Narrower (2)

KeytrudaMK-3475

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency
Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease of the CNS, which develops almost… 
2019
2019
Ineffective treatment of PML with pembrolizumab
Progressive multifocal leukoencephalopathy (PML) is a rare pathologic CNS condition caused by JC polyomavirus (JCPyV) in… 
2019
2019
First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma (mEGA).
62 Background: Trastuzumab stimulates HER2-specific T cell responses and increases tumor PD-L1 expression, and anti-PD-1 antibody… 
2017
2017
Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC).
6009Background: Somatic mutational load (ML) is associated with response to anti CTLA-4 and PD-1/-L1 immunotherapies in select… 
2017
2017
Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.
TPS4590Background: Only 5%-15% of patients (pts) with advanced bladder cancer attain long-term survival with standard first-line… 
Highly Cited
2017
Highly Cited
2017
A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC).
4506Background: PAZ is indicated for the treatment of aRCC. The combination of an anti-angiogenic agent and immunotherapy may… 
Highly Cited
2016
Highly Cited
2016
Updated results for the advanced esophageal carcinoma cohort of the phase 1b KEYNOTE-028 study of pembrolizumab.
7 Background: PD-L1 and PD-L2 expression have been associated with poor prognosis in esophageal cancer. Pembrolizumab (pembro) is… 
Highly Cited
2016
Highly Cited
2016
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.
9504Background: In the phase III KEYNOTE-006 study (NCT01866319), pembro (anti–PD-1) provided superior OS and PFS and a lower… 
Highly Cited
2015
Highly Cited
2015
Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
9005 Background: The anti–PD-1 antibody pembro is approved in the US for treating unresectable or metastatic MEL that progressed… 
Highly Cited
2014
Highly Cited
2014
Lambrolizumab induced central nervous system (CNS) toxicity
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)